Why Corp Travel Management (ASX:CTD) and Starpharma (ASX:SPL) shares are in trading halts

Corporate Travel Management Ltd (ASX:CTD) and Starpharma Holdings Limited (ASX:SPL) shares are in trading halts on Monday. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The market may be pushing higher this afternoon but missing out on the action are the shares of Corporate Travel Management Ltd (ASX: CTD) and Starpharma Holdings Limited (ASX: SPL).

Both companies requested trading halts this morning before the market open. Here's why they are halted:

Corporate Travel Management

The Corporate Travel Management share price was placed into a trading halt this morning until Thursday whilst it undertakes the institutional component of an accelerated entitlement offer. According to the request, unlike many of its peers, the company isn't raising funds for liquidity. Rather, it is raising these funds to make a potential acquisition.

No details were given with the release, but the AFR has reported that Corporate Travel Management is understood to be raising $400 million to make a company-changing acquisition. It remains unclear which company management has its eyes on. And given that it operates globally, there certainly are a lot of options for it to choose from.

Starpharma

The Starpharma share price has gone into a trading halt on Monday so that the dendrimer products developer can launch an equity raising. This will comprise an institutional placement and an accompanying share purchase plan. Starpharma's shares are expected to return to trade on Wednesday following the completion of the institutional component of the equity raising.

Once again, no details were given with the trading halt request. However, the company is understood to be looking to raise a total of $45 million from investors at a price of $1.50 per new share. This represents a 6.5% discount to its last close price. Some of the funds are expected to be used to support the commercialisation and launch of its COVID-19 nasal spray. Other funds are likely to be used towards the advancement of its promising DEP drug delivery technology.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia owns shares of and has recommended Corporate Travel Management Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Broker Notes

Guess which ASX 300 stock was downgraded to sell today

Bell Potter has become bearish on this stock. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX gave up an afternoon lead to close lower today.

Read more »

a gas worker with hard hat and high visibility vest stands cross armed and smiling in front of an elaborate steel structured gas plant.
Share Market News

Morgans names 2 ASX energy shares to buy now

These shares could be top picks for investors with a high tolerance for risk.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Broker Notes

Is the ResMed share price still cheap? What the numbers say

Let's see what analysts are saying about this blue chip as it nears a 52-week high.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Broker Notes

What does Macquarie think REA shares are worth?

Top broker Macquarie has reviewed its rating and price target on REA shares.

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Aurelia Metals, Centuria Office, Meeka Metals, and Resolute shares are tumbling today

These shares are having a tough time on Thursday. Let's find out why.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Clarity Pharmaceuticals, Kelsian, Life360, and Syrah shares are rising today

These shares are pushing higher on Thursday. But why?

Read more »

Woman checking out new TVs.
Broker Notes

Does JP Morgan think JB Hi-Fi shares can keep rising?

The retailer is up 16% for the year to date.

Read more »